Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset

Dokument -

Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset

Isofol Medical AB announces it has launched a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset. The Sage Group is appointed to assist the company in this endeavor. The objective is to identify a pharma partner who will work with the company to exploit the value of Modufolin® in what is believed to be a multi billion dollar market.
  • Licens: All rights reserved
    Innehållet får bara användas av Mynewsdesk. Det är alltså inte tillåtet för någon annan att ladda ner, kopiera, sprida eller på annat sätt använda Innehållet (annat än för privat bruk i den mån det följer av lag).
  • Filformat: .pdf

Kontakter

Anders Rabbe

Presskontakt CEO +46 (0)707 646 500

Jan-Eric Österlund

Presskontakt Executive Chairman + 44 7785 368155

Relaterat innehåll

Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset

Isofol Medical AB announces it has launched a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset. The Sage Group is appointed to assist the company in this endeavor. The objective is to identify a pharma partner who will work with the company to exploit the value of Modufolin® in what is believed to be a multi billion dollar market.